PC
SBBP

PA Capital’s Strongbridge Biopharma plc. SBBP Stock Holding History

PA Capital’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-77,799
Closed -$163K – 190
2019
Q4 		$163K Sell
77,799
-75,178
-49% -$144K 0.14% 119
2019
Q3 		$366K Buy
+152,977
New +$411K 0.36% 93
2019
Q2 		– Sell
-52,824
Closed -$263K – 125
2019
Q1 		$263K Buy
+52,824
New +$260K 0.23% 95

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PA Capital's SBBP Position: Q1 2020 in Review

PA Capital sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2020, closing a stake of 77,799 shares — an estimated $163K sold.

PA Capital first reported a position in SBBP in Q1 2019 and held it in 3 quarters. The position peaked at $366K in Q3 2019. 60 funds tracked by Wall St. Rank hold SBBP as of Q1 2020.

  • PA Capital reported no remaining Strongbridge Biopharma plc. position as of Q1 2020 after selling out during the quarter.
  • PA Capital sold 77,799 Strongbridge Biopharma plc. shares in Q1 2020, an estimated $163K.
  • PA Capital first reported a position in Strongbridge Biopharma plc. in Q1 2019 and held it in 3 quarters.
  • PA Capital's Strongbridge Biopharma plc. position peaked at $366K in Q3 2019.
  • 60 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2020.

Based on PA Capital's 13F filing for Q1 2020, filed 11 May 2020.